Cargando…
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
INTRODUCTION: The amounts of estrogen receptor (ER) and progesterone receptor (PgR) in a primary tumor are predictive of the response to endocrine therapies of breast cancer. Several patients with ER-positive primary tumors relapse after adjuvant endocrine therapy with no ER expression in the recurr...
Autores principales: | Munzone, Elisabetta, Curigliano, Giuseppe, Rocca, Andrea, Bonizzi, Giuseppina, Renne, Giuseppe, Goldhirsch, Aron, Nolè, Franco |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413988/ https://www.ncbi.nlm.nih.gov/pubmed/16417653 http://dx.doi.org/10.1186/bcr1366 |
Ejemplares similares
-
Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006) -
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
por: Schmid, Sabine, et al.
Publicado: (2019) -
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006) -
A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
por: Rocca, A, et al.
Publicado: (2009) -
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)